Group 1 - Catalyst Pharmaceutical (CPRX) closed at $24.96, with a 0.5% gain over the past four weeks, and a mean price target of $34 indicates a 36.2% upside potential [1] - The average price targets range from a low of $31 to a high of $40, with a standard deviation of $2.98, suggesting a 24.2% to 60.3% upside potential [2] - Analysts show strong agreement on CPRX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 3.5% over the last 30 days, with four estimates moving higher and no negative revisions [12] - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [13]

Core Viewpoint - Provident Financial (PFS) shows potential for significant upside, with a mean price target of $21.50 indicating a 28.1% increase from the current price of $16.78 [1] Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $18 to a high of $24, with a standard deviation of $2.17, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a 7.3% increase, while the highest suggests a 43% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about PFS's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with two estimates moving higher and no negative revisions [12] - PFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Syndax Pharmaceuticals (SNDX) shows significant upside potential with a mean price target of $35.23, indicating a 220% increase from the current price of $11.01 [1] Price Targets and Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $10.34, suggesting variability among analysts [2] - The lowest estimate of $17 indicates a 54.4% increase, while the highest estimate predicts a surge of 363.2% to $51 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about SNDX's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 5.6% over the past month, with four estimates increasing and no negative revisions [12] - SNDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Extreme Networks (EXTR) has shown a significant price increase of 26.3% over the past four weeks, with a mean price target of $18.75 indicating a potential upside of 33.8% from the current price of $14.01 [1] - The mean estimate consists of six short-term price targets with a standard deviation of $3.31, suggesting variability in analyst predictions; the lowest estimate is $15 (7.1% increase), while the highest is $22.50 (60.6% increase) [2] - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, indicating a positive outlook for EXTR [11][12] Group 2 - The Zacks Consensus Estimate for EXTR's current year earnings has increased by 4.9% over the last 30 days, with two estimates moving higher and no negative revisions [12] - EXTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13] - While price targets can be misleading, the direction implied by the consensus price target for EXTR appears to be a useful guide for potential price movement [10][13]

Core Viewpoint - Byline Bancorp (BY) shares have increased by 3% recently, closing at $25.76, with analysts suggesting a potential upside of 25.8% based on a mean price target of $32.40 [1][11]. Price Targets and Analyst Estimates - The mean estimate for BY's price comprises five short-term targets with a standard deviation of $2.30, indicating a range of estimates from a low of $29 (12.6% increase) to a high of $34 (32% increase) [2][11]. - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BY's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 1.3% over the past month, with two estimates increasing and no negative revisions [12]. Zacks Rank and Investment Potential - BY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].

Core Viewpoint - CPI Card Group Inc. (PMTS) has shown a 1.3% increase in share price over the past four weeks, closing at $29.03, with a potential upside of 27.5% based on Wall Street analysts' mean price target of $37 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.94, indicating variability among analysts; the lowest estimate of $33 suggests a 13.7% increase, while the highest target of $40 indicates a potential surge of 37.8% [2] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts regarding PMTS's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with one estimate moving higher and no negative revisions [10] - PMTS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Caution on Price Targets - While consensus price targets are a popular metric, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][5][8]

Core Viewpoint - ACM Research, Inc. (ACMR) has shown a significant price increase of 22% over the past four weeks, with analysts projecting a mean price target of $34.43, indicating a potential upside of 41.6% from the current price of $24.31 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $26 to a high of $40, with a standard deviation of $4.69, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 7% increase, while the highest suggests a 64.5% upside, highlighting the range of potential outcomes [2] Analyst Sentiment - There is strong agreement among analysts regarding ACMR's ability to exceed previous earnings predictions, which supports the expectation of an upside [4][9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 40.4%, with no negative revisions, indicating positive sentiment [10] Zacks Rank - ACMR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, which further indicates potential upside [11] Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction implied by these targets appears to be a useful guide for potential price movements [12]